Jane Lisko, MD
Micrographic Dermatologic Surgery · Fridley, MNNPI 1619910890
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $8,393 of the $9,516 with a category attached, or 88.2%. AbbVie accounts for 90.7% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2021 at $4,346 and has fallen 95.4% since, to $201 in 2025.
Across 62 payments — averaging $153.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$9K
- Regeneron Healthcare Solutions, Inc.$141
- Sanofi$115
- Incyte Corporation$80
- Mimedx Group, Inc.$77
- Biofrontera Inc.$71
- plus $403 from 15 others
What the payments were for
- Speaking & faculty fees$8,39388%
- Food & beverage$1,10812%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 7 | $8,628 |
| Regeneron Healthcare Solutions, Inc. | 9 | $141 |
| Sanofi | 7 | $115 |
| Incyte Corporation | 5 | $80 |
| Mimedx Group, Inc. | 3 | $77 |
| Biofrontera Inc. | 4 | $71 |
| Lilly USA, LLC | 5 | $69 |
| Novartis | 3 | $44 |
| Johnson & Johnson | 3 | $44 |
| LEO Pharma Inc. | 3 | $44 |
| Bristol Myers Squibb | 2 | $38 |
| Surgenex LLC | 1 | $35 |
| Amgen | 2 | $33 |
| DUSA Pharmaceuticals, Inc. | 1 | $16 |
| Arcutis Biotherapeutics, Inc. | 1 | $14 |
| Sun Pharmaceutical Industries Inc. | 1 | $13 |
| Pfizer | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Dermira, Inc. | 1 | $12 |
| Galderma Laboratories, L.p. | 1 | $11 |
| Organon | 1 | $5 |
How this compares
Too few micrographic dermatologic surgery providers in Minnesotato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluorouracil | 42 | $3,383 |
| Metronidazole | 24 | $2,422 |
| Ketoconazole | 94 | $2,417 |
| Betamethasone Dipropionate | 32 | $1,529 |
| Fluocinonide | 39 | $1,438 |
| Mupirocin | 149 | $966 |
| ValacyclovirValacyclovir Hcl | 43 | $953 |
| Doxycycline Hyclate | 23 | $737 |
| Triamcinolone Acetonide | 50 | $573 |
| Clindamycin Phosphate | 11 | $500 |
| Cephalexin | 26 | $349 |
| Clobetasol Propionate | 13 | $199 |
| Terbinafine Hcl | 12 | $98 |
| Hydroxyzine Hcl | 13 | $61 |
Paid to pharmacies, not to this prescriber.
Other micrographic dermatologic surgery in Fridley
- Stephen TanSaint Paul$0
- Randall RoenigkRochester$0
- Jerry BrewerRochester$0
- Christian BaumRochester$0
- Mary LohmanRochester$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.